FAS/FASL Expression Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Oral Cavity

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  de Carvalho Neto, Paulo Bentes ^a   Santos, Marcelo dos ^b   de Carvalho, Marcos Brasilino ^a   da Mercante, Ana Maria Cunha ^a   Santos, Viviane Priscila Pina dos ^a   Severino, Patrícia ^c   Tajara, Eloiza Helena ^d   Louro, Iuri Drumond ^b   da Silva Conforti, Adriana Madeira Álvares ^b  

^a HOSPITAL HELIÓPOLIS   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; ORAL SURGERY; RISK FACTOR;

ADULT; AGED; ANTIGENS, CD95; CARCINOMA, SQUAMOUS CELL; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84880432062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069024     Document Type: Article

References (50)

1. Bauman JE, Michel LS, Chung CH, (2012) New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 24: 235-242.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer: Available: http://globocan.iarc.fr. Accessed 20 July 2012.
3. Myers EM, Fagan JJ, (1998) Treatment of the N+ neck in squamous cell carcinoma of the upper aerodigestive tract. Otolaryngol Clin North Am 31: 671-686.
4. Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, et al. (2004) The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 26: 660-674.
5. Pentenero M, Gandolfo S, Carrozzo M, (2005) Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head Neck 27: 1080-1091.
6. Shibakita M, Tachibana M, Dhar DK, Ohno S, Kubota H, et al. (2000) Spontaneous apoptosis in advanced esophageal carcinoma: its relation to Fas expression. Clin Cancer Res 6: 4755-4759.
7. Zhang X, Miao X, Sun T, Tan W, Qu S, et al. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42: 479-484.
8. Volm M, Koomagi R, (2000) Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 82: 1747-1754.
9. Sun T, Miao X, Zhang X, Tan W, Xiong P, et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030-1036.
10. Ashkenazi A, Dixit VM, (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Bio 11: 255-260.
11. French LE, Tschopp J, (2003) Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 10: 117-123.
12. Ashe PC, Berry MD, (2003) Apoptotic signaling cascades. Prog Neuropsychopharmacol Biol Psychiatry 27: 199-214.
13. Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, et al. (2000) Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol 7: 750-757.
14. Severino P, Alvares AM, Michaluart P Jr, Okamoto OK, Nunes FD, et al. (2008) Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes 1: 113.
15. Deschler DG, Day T (2008) Pocket Guide to Neck Dissection and Classification and TNM Staging of Head and Neck Cancer. American Academy of Otolaryngology-Head and Neck Surgery Foundation. 28 p.
16. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E, (2001) Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70: 255-264.
17. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, et al. (2002) Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33: 968-974.
18. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, et al. (2002) Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15: 1374-1380.
19. Soini Y, Kahlos K, Puhakka A, Lakari E, Saily M, et al. (2000) Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 3: 880-886.
20. Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA, (2009) Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol Cell Biochem 321: 95-102.
21. DeLong MJ, (1998) Apoptosis: a modulator of cellular homeostasis and disease states. Ann NY Acad Sci 842: 82-90.
22. Brill A, Torchinsky A, Carp H, Toder V, (1999) The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet 16: 512-519.
23. Morita Y, Tsutsumi O, Taketani Y, (2001) Regulatory mechanisms of female germ cell apoptosis during embryonic development. Endocr J 48: 289-301.
24. Doseff AI, (2004) Apoptosis: the sculptor of development. Stem Cells Dev 13: 473-483.
25. McGill G, Fisher DE, (1997) Apoptosis in tumorigenesis and cancer therapy. Front Biosci 2: 353-379.
26. Sjostrom J, Bergh J, (2001) How apoptosis is regulated, and what goes wrong in cancer. BMJ 322: 1538-1539.
27. Koornstra JJ, de Jong S, Hollema H, de Vries EG, Kleibeuker JH, (2003) Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 45: 37-53.
28. Gerl R, Vaux DL, (2005) Apoptosis in the development and treatment of cancer. Carcinogenesis 26: 263-270.
29. Vermeulen K, Van Bockstaele DR, Berneman ZN, (2005) Apoptosis: mechanisms and relevance in cancer. Ann Hematol 84: 627-639.
30. King KL, Cidlowski JA, (1995) Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 58: 175-180.
31. Yuo A, (2001) Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism. Int J Hematol 73: 438-452.
32. Blagosklonny MV, (2003) Apoptosis, proliferation, differentiation: in search of the order. Semin Cancer Biol 13: 97-105.
33. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, et al. (1998) Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 58: 2057-2062.
34. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, et al. (1999) The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30: 413-421.
35. Fan CF, Xu HT, Lin XY, Yu JH, Wang EH, (2011) A multiple marker analysis of apoptosis-associated protein expression in non-small cell lung cancer in a Chinese population. Folia Histochemica et Cytobiologica 49: 231-239.
36. Watson GA, Naran S, Zhang X, Stang MT, Oliveira PEQ, et al. (2011) Cytoplasmic Overexpression of CD95L in Esophageal Adenocarcinoma Cells Overcomes Resistance to CD95-Mediated Apoptosis. Neoplasia 13: 198-205.
37. Asensio C, Zapata A, García-Ahijado J, Gil B, Salvadores P, (2007) Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. Anticancer Res 27: 4083-4086.
38. Pryczynicz A, Guziñska-Ustymowicz K, Kemona A, (2010) Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem Cytobiol 48: 425-429.
39. Li Q, Peng J, Li XH, Liu T, Liang QC, et al. (2010) Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues. World J Gastroenterol 16: 1274-1278.
40. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, et al. (1999) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18: 3754-3760.
41. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, et al. (1998) Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinoma. J Clin Invest 101: 1102-1110.
42. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, et al. (1997) Human lung carcinomas express Fas ligand. Cancer Res 57: 1007-1012.
43. Owen-Schaub LB, van Golen KL, Hill LL, Price JE, (1998) Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 188: 1717-1723.
44. Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, et al. (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57: 371-377.
45. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, et al. (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59: 5356-5364.
46. Farshadpour F, Kranenborg H, Calkoen EVB, Hordijk GJ, Koole R, et al. (2011) Survival analysis of head and neck squamous cell Carcinoma: influence of smoking and drinking. Head Neck 33: 817-823.
47. Szabo G, (1999) Consequences of alcohol consumption on host defence. Alcohol and Alcoholism 34: 830-841.
48. Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA, (2008) Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 83: 774-874.
49. Accomando WP, Wiencke JK, Houseman EA, Butler RA, Zheng S, et al. (2012) Decreased NK Cells in Patients with Head and Neck Cancer Determined in Archival DNA. Clin Cancer Res 18: 6147-6154.
50. Gonçalves RB, Coletta RD, Silvério KG, Benevides L, Casati MZ, et al. (2011) Impact of smoking on inflammation: overview of molecular. Mechanisms Inflamm. Res 60: 409-424.